The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | AutoSCT versus consolidation chemotherapy as post-remission treatment in newly diagnosed AML
Dimitrios Kotsos, MD, Erasmus MC, Rotterdam, Netherlands, discusses the findings of an analysis using data from two recent HOVON-SAKK-Nordic clinical trials, which compared autologous stem cell transplantation (autoSCT) to consolidation chemotherapy as post-remission treatment in newly diagnosed favorable- and intermediate-risk patients with acute myeloid leukemia (AML) in a measurable residual disease (MRD)-negative complete remission (CR). Dr Kotsos highlights that the study found similar relapse-free survival (RFS) and overall survival (OS) rates between the two groups, with some differences in adverse events, and suggests that chemotherapy may be the preferred option given the potential to add novel targeted agents. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
High-dose chemotherapy followed by autologous stem cell transplant and consolidation chemotherapy are post-remission strategy options for ELN 2022 favorable and intermediate risk patients in an MRD negative complete remission. In our analysis, we compared these two modalities and we focused on favorable- and intermediate-risk patients that were intensively treated...
High-dose chemotherapy followed by autologous stem cell transplant and consolidation chemotherapy are post-remission strategy options for ELN 2022 favorable and intermediate risk patients in an MRD negative complete remission. In our analysis, we compared these two modalities and we focused on favorable- and intermediate-risk patients that were intensively treated. For this purpose, we pulled data from two recent HOVON-SAKK-Nordic clinical trials.
The auto group consisted of patients that received busulfan and cyclophosphamide, followed by autologous stem cell transplant, and the chemo group consisted of patients that received mitoxantrone and etoposide as consolidation. In total, 224 patients were consolidated with auto and 199 with consolidation chemotherapy. Relapse-free survival, overall survival, cumulative incidence of relapse, and non-relapse mortality were similar between the two groups. With regards to the adverse events, grade 3 to 5 oral mucositis was more common in the auto group and grade 3 to 5 pneumonia was more common in the chemo group. Moreover, days until count recovery and days of hospitalization were longer in the chemo group.
Focusing on MRD negative patients in the favorable risk group, RFS and OS were similar, and this was also true for the intermediate MRD negative patients, so I guess no difference in RFS and OS between the two modalities. In further subgroup analysis, patients that got a late complete remission after induction, so the patients that got to CR after cycle 2 of induction, and those that had elevated white blood cell count at diagnosis, had a better relapse-free survival with autologous stem cell transplant, but this did not translate into a better OS. Overall, chemotherapy appears to be the preferred option since it allows for the addition of novel targeted agents.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
